Back

prof. dr. H.G.M. (Harry) Heijerman

prof. dr. H.G.M. (Harry) Heijerman

Full Professor
  • Department of Pulmonary Diseases

Research Programs

Infection & Immunity

Research Output (65)

CFTR Modulators:Does One Dose Fit All?

van der Meer Renske, Wilms Erik B, Heijerman Harry G M jun 2021, In: Journal of Personalized Medicine. 11 12 p.

New Insights in Adherence and Survival in Myotonic Dystrophy Patients Using Home Mechanical Ventilation

Seijger Charlotte, Raaphorst Joost, Vonk Judith, van Engelen Baziel, Heijerman Harry, Stigter Nadine, Wijkstra Peter 2021, In: Respiration. 100 , p. 154-163 10 p.

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Berkers Gitte, van der Meer Renske, van Mourik Peter, Vonk Annelotte M, Kruisselbrink Evelien, Suen Sylvia Wf, Heijerman Harry Gm, Majoor Christof J, Koppelman Gerard H, Roukema Jolt, Janssens Hettie M, de Rijke Yolanda B, Kemper E Marleen, Beekman Jeffrey M, van der Ent Cornelis K, de Jonge Hugo R nov 2020, In: Journal of Cystic Fibrosis. 19 , p. 955-961 7 p.

Resting energy expenditure in cystic fibrosis patients decreases after lung transplantation, which improves applicability of prediction equations for energy requirement

Hollander-Kraaijeveld Francis, Van Lanen A.S., de Roos N M, van de Graaf EA, Heijerman Harry nov 2020, In: Journal of Cystic Fibrosis. 19 , p. 975-980 6 p.

Effectiveness of pulmonary rehabilitation at high-altitude compared to sea-level in adults with severe refractory asthma

de Nijs S B, Krop E J M, Portengen L, Rijssenbeek-Nouwens L H, de Vries D, Weersink E J M, Heijerman H G M, Heederik D J J, Lammers J W J sep 2020, In: Respiratory Medicine. 171 , p. 1-11

Transparency and diversity in cystic fibrosis research - Authors' reply

McCoy Karen S, Heijerman Harry, Taylor-Cousar Jennifer L, Waltz David, Sosnay Patrick R, Ramsey Bonnie W, Rowe Steven, Welter John 29 aug 2020, In: The Lancet. 396 , p. 602 1 p.

Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation

Burghard M., Berkers G., Ghijsen S., Hollander-Kraaijeveld F. M., de Winter-de Groot K. M., van der Ent C. K., Heijerman H. G.M., Takken T., Hulzebos H. J. jun 2020, In: Pediatric Pulmonology. 55 , p. 1400-1405 6 p.

Does Circadian Rhythm affect the Pharmacokinetics of Once-Daily Tobramycin in Adults with Cystic Fibrosis?

van Maarseveen E M, van der Meer R, Neef C, Heijerman H G M, Touw D J 11 feb 2020, In: Therapeutic Drug Monitoring. 42 , p. 595-599 5 p.

Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV<sub>1</sub> ≥ 90% predicted at baseline

Aalbers B L, de Winter-de Groot K M, Arets H G M, Hofland R W, de Kiviet A C, van Oirschot-van de Ven M M M, Kruijswijk M A, Schotman S, Michel S, van der Ent C K, Heijerman H G M 7 jan 2020, In: Journal of Cystic Fibrosis. 19 , p. 654-658 5 p.

Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males

Aalbers B. L., Hofland R. W., Bronsveld I., de Winter-de Groot K. M., Arets H. G.M., de Kiviet A. C., van Oirschot-van de Ven M. M.M., Kruijswijk M. A., Schotman S., Michel S., van der Ent C. K., Heijerman H. G.M. 1 jan 2020, In: Journal of Cystic Fibrosis. 20 , p. e7-e11

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet